** Shares of drug developer Acadia Pharmaceuticals ACAD.O rise 34.2% to over 1-year high of $23.61
** U.S. District Court for the District of Delaware has ruled that India's Aurobindo Pharma infringes on two of Acadia Pharmaceuticals' patent claims
** The court has rejected Aurobindo's arguments that they are invalid
** The companies will meet to discuss next steps and submit a joint letter to the court within 21 days
** Acadia will provide an update on its revised stipulation regarding the patent claims within 7 days
** Companies must work together to redact sensitive information from the court's opinion and submit a proposed redacted version within 30 days
** Including session's move, stock up 28.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。